What is it about?
This paper reported risk of liver-related adverse events and correlation with underlying viral hepatitis from the IMBrave150 randomized trial. This trial compared the efficacy/ safety of atezolizumab plus bevacizumab with sorafenib, and the results set the new standard of care for patients with advanced liver cancer.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Cancer patients with chronic viral hepatitis infection were generally excluded from oncology new drug clinical trials, particularly in the early-phase development stage, for fear of increased risk of adverse events. Our study demonstrated that, with adequate antiviral therapy and regular monitoring, the risk and severity of liver-related adverse events may not be related to reactivation of underlying viral hepatitis infection.
Perspectives
Results of this study may increase the opportunity of cancer patients with chronic viral hepatitis to participate in clinical trials of new oncology drugs.
Chiun Hsu
National Taiwan University Cancer Center
Read the Original
This page is a summary of: Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab, Liver Cancer, August 2022, Karger Publishers,
DOI: 10.1159/000525499.
You can read the full text:
Contributors
The following have contributed to this page
